MedTrace Logo

Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)

NCT01001143 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2014-07-29

No results posted yet for this study

Summary

The main objective is to determine the safety and tolerability of combination decitabine and bexarotene during four cycles of therapy.

Conditions

  • Leukemia, Myeloid, Acute

Interventions

DRUG

Decitabine

DRUG

Bexarotene

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Amanda Cashen, M.D. · Washington University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2013-05-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01001143 on ClinicalTrials.gov